www.bio-itworld.com/newsitems/2007/april/copy_of_04-19- -
[Cached Version]
Published on: 4/26/2007
Last Visited: 4/26/2007
EDC capabilities are important in landing investigator-initiated trials (IITs) and registry business, says JeanMarie Markham, president and CEO of ClinLogix.IITs represent about half of the trials managed by the 17-year-old CRO.Clinipace was a "good fit" because of its expertise in this arena."It's a great little company.The people there are very responsive."
ClinLogix is currently working on one of the "few bigger" investigator-initiated oncology trials using EDC, says Markham."We customize trial work to fit the needs of clients" - in this case, with EDC as well as a project team whose members each have at least five years of oncology experience.The investigator network was pleasantly surprised by TEMPO's affordability, she adds.
"[EPP] has really helped bolster our service offering," says Markham.
2 online sources [ view sources ]
Profile is not claimed [ this is me ]
